Journal of Shanghai University(Natural Science Edition) ›› 2016, Vol. 22 ›› Issue (3): 357-365.doi: 10.3969/j.issn.1007-2861.2016.03.017

Previous Articles     Next Articles

Effects of Chinese patent medicines on left ventricular ejection fraction and brain natriuretic peptide in patients with chronic heart failure: systematic review#br# and Meta-analysis

LIU Shuo1, LI Min1, CHEN Shiqi1, QIU Ruijin1, ZHANG Qin1, ZHAO Mingjing1, CHEN Jing2, SHANG Hongcai1   

  1. 1. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
    2. Department of Health, Baokang Hospital, Tianjin University of Chinese Medicine, Tianjin 300193, China
  • Received:2016-04-20 Online:2016-06-30 Published:2016-06-30

Abstract:

To evaluate efficacy and security of Chinese patent medicines on left ventricular ejection fraction (LVEF) and plasma brain natriuretic peptide (BNP) in the treatment of heart failure (HF). Five databases including PubMed, The Cochrane Library, CNKI, VIP and WanFang Data have been searched to identify relevant randomized controlled trials (RCTs) up till March 2016. Methodological quality of the included studies was assessed using criteria from Cochrane Reviewer’s Handbook 5.3, and analyzed using Rev Man 5.3 software. Sixteen RCTs of Chinese patent medicines were included. Results of the Meta-analysis showed that Chinese patent medicines were more effective on LVEF (MD=5.80, 95%CI (confidence interval): 0.236.73, P < 0.01) and BNP (MD= −366.99, 95%CI: −412.00  −321.97, P < 0.01). In addition, assessed quality of the included randomized controlled trials were low. Based on low quality and limited data, Chinese patent medicines were more significant at the LVEF and BNP level. Therefore, sufficient high quality experiments need to be conducted to confirm efficacy and security of Chinese patent medicines.

Key words:  chronic heart failure ,  Meta analysis,  systematic review , Chinese patent medicine